What is the 13F Pro Quality Score for IDXX?

13F Pro ranks IDEXX LABORATORIES INC /DE (IDXX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View IDXX's current score at https://13fpro.ai/research/IDXX (free sign-up required for the full ranking).

Where does 13F Pro source IDXX data?

All IDEXX LABORATORIES INC /DE fundamentals and ownership data come directly from SEC EDGAR. IDEXX LABORATORIES INC /DE files with the SEC under CIK 874716. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is IDXX in?

IDEXX LABORATORIES INC /DE (IDXX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is IDXX research updated on 13F Pro?

IDXX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

IDEXX LABORATORIES INC /DE(IDXX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 874716 IDXX stock profile & AI dashboard →

13F Pro Quality Score

73.6/100

Rank #189 of 2,879 stocksTOP 10%

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

60.5/100

Profitability

88.6/100

Balance Sheet

98.9/100

Earnings Quality

56.5/100

Free Cash Flow

80.2/100

Institutional Flow

4.6/100

Revenue Scale

76.1/100

Dilution Risk

48.7/100

IDXX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for IDEXX LABORATORIES INC /DE (IDXX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IDXX at 73.6/100 on a 32-signal composite quality model, placing it at rank #189 of 2,879 stocks — the top 10% of the AI-ranked universe. IDXX scores in the top quartile across balance sheet strength (98.9), profitability (88.6), free cash flow (80.2). Areas of concern include institutional flow (4.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 48.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), IDEXX LABORATORIES INC /DE reports quarterly revenue of $1.1B, net income of $278.4M, an operating margin of 31.8%. IDXX trades on the Nasdaq exchange and files with the SEC under CIK 874716. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IDXX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for IDEXX LABORATORIES INC /DE directly from SEC EDGAR. IDEXX LABORATORIES INC /DE's 13F Pro composite quality score has ranged between 8 and 79 since 2021, currently 73.6 — a stable long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about IDEXX LABORATORIES INC /DE

Quirks, history, and lore behind IDXX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · large-cap · listed on Nasdaq · headquartered in Maine.
2
The Numbers
Annual revenue around $3.5 billion, with operating margins that make pharma executives jealous — because it sells tests and instruments, not pills.
3
The History
Founded in the 1980s, it carved out a dominant niche by focusing exclusively on veterinary diagnostics — a market most healthcare giants ignored entirely.
4
The Secret
The real money is a classic razor-and-blades model: place the analyzer in the clinic, then sell a steady stream of consumable test cartridges for years.
5
The Lore
It is essentially the dominant monopoly of pet diagnostics — vets rely on it the way hospitals rely on Quest, and switching costs keep them locked in for life.
6
The Giveaway
If your dog just got blood work at the vet, there's a very good chance the machine was a Catalyst One and the bill was processed through this company's IDEXX VetLab platform.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$1.1B

Net Income

Q1 2026

$278.4M

Free Cash Flow

Q1 2026

$234.3M

Operating Margin

Q1 2026

31.8%

D/E Ratio

Q1 2026

0.29

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.4% YoY

$4.30BFY 2025

FY22 $3.37BFY23 $3.66BFY24 $3.90BFY25 $4.30B

Net Income

+19.3% YoY

$1.06BFY 2025

FY22 $679.1MFY23 $845.0MFY24 $887.9MFY25 $1.06B

Operating Income

+20.5% YoY

$1.36BFY 2025

FY22 $898.8MFY23 $1.10BFY24 $1.13BFY25 $1.36B

EPS (Diluted)

+22.6% YoY

$13.08FY 2025

FY22 $8.03FY23 $10.06FY24 $10.67FY25 $13.08

Total Assets

+1.7% YoY

$3.35BFY 2025

FY22 $2.75BFY23 $3.26BFY24 $3.29BFY25 $3.35B

Total Debt

-33.2% YoY

$525.0MFY 2025

FY22 $844.8MFY23 $773.2MFY24 $785.6MFY25 $525.0M

Op. Cash Flow

+27.2% YoY

$1.18BFY 2025

FY22 $543.0MFY23 $906.5MFY24 $929.0MFY25 $1.18B

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$4.30B +10.4%	$3.90B +6.5%	$3.66B +8.7%	$3.37B +4.7%	$3.22B +18.8%	$2.71B
Net Income	$1.06B +19.3%	$887.9M +5.1%	$845.0M +24.4%	$679.1M -8.8%	$744.8M +28.0%	$581.8M
Operating Income	$1.36B +20.5%	$1.13B +2.8%	$1.10B +22.1%	$898.8M -3.6%	$932.0M +34.2%	$694.5M
EPS (Diluted)	$13.08 +22.6%	$10.67 +6.1%	$10.06 +25.3%	$8.03 -6.6%	$8.60 +28.2%	$6.71
Total Assets	$3.35B +1.7%	$3.29B +1.0%	$3.26B +18.7%	$2.75B +12.7%	$2.44B +6.2%	$2.29B
Total Debt	$525.0M -33.2%	$785.6M +1.6%	$773.2M -8.5%	$844.8M -8.7%	$925.7M -3.5%	$959.1M
Operating Cash Flow	$1.18B +27.2%	$929.0M +2.5%	$906.5M +66.9%	$543.0M -28.1%	$755.5M +16.6%	$648.1M

Get alerted when IDXX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for IDEXX LABORATORIES INC /DE including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put IDXX on your watchlist

Track score changes the day IDEXX LABORATORIES INC /DE files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is IDXX a good stock to buy?

13F Pro's AI-powered analysis of IDEXX LABORATORIES INC /DE (IDXX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for IDXX are available on the IDXX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own IDXX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling IDXX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of IDEXX LABORATORIES INC /DE's investment landscape.